Avutometinib + Defactinib for Ovarian Cancer
(RAMP 301 Trial)
Trial Summary
What is the purpose of this trial?
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Will I have to stop taking my current medications?
The trial requires that you have not had any systemic anti-cancer therapy within 4 weeks before starting the study treatment. This means you may need to stop certain cancer medications before joining the trial.
What makes the drug combination Avutometinib + Defactinib unique for ovarian cancer treatment?
The combination of Avutometinib and Defactinib is unique because it targets specific pathways involved in cancer cell growth, potentially offering a new approach for patients with ovarian cancer, especially those with certain genetic profiles. This combination may provide an alternative for patients who do not respond well to standard platinum-based chemotherapy.12345
Research Team
Rachel Grisham, MD
Principal Investigator
GOG Foundation
Susana Banerjee, MBBS, MA, PhD
Principal Investigator
European Network of Gynecological Oncological Trial Groups (ENGOT)
Melina Arazy, MD Verastem Medical Monitor
Principal Investigator
RAMP301@verastem.com
Eligibility Criteria
This trial is for individuals with recurrent low-grade serous ovarian cancer (LGSOC) who have seen their cancer return or worsen after at least one systemic therapy. Participants must have a certain level of physical fitness (ECOG ≤ 1), measurable disease, and good organ function. They should be recovered from previous treatment side effects and agree to use effective contraception if they can have children.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the investigational combination of avutometinib plus defactinib or Investigator's Choice of Treatment in 28-day cycles
Follow-up
Participants are monitored for safety, overall survival, and progression-free survival after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term if they initially received standard care and have progressive disease
Treatment Details
Interventions
- Avutometinib
- Defactinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Verastem, Inc.
Lead Sponsor
GOG Foundation
Collaborator
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Collaborator
Australia New Zealand Gynaecological Oncology Group
Collaborator
Korean Gynecologic Oncology Group
Collaborator